SOS1 Inhibitor
-
SOS1-IN-25
0 ImagesCat. No.: HY-179443CAS No.: 3092446-09-5
-
SOS1-IN-19
0 ImagesCat. No.: HY-176170SOS1-IN-19 (Compound 10i) is a potent inhibitor of SOS1 (Son of Sevenless 1) with an IC50 value of 165.2 nM. SOS1-IN-19 blocks KRAS activation by preventing GDP/GTP exchange in KRAS signaling pathway. SOS1-IN-19 is promising for research of KRAS-driven cancers (e.g., NSCLC and colorectal cancer).
-
SOS1 Ligand intermediate-4
0 ImagesCat. No.: HY-161635CAS No.: 3036155-94-6SOS1 Ligand intermediate-4 is a ligand of SOS1, used for the synthesis of PROTAC SOS1 degrader (HY-161634).
-
SOS1-IN-3
0 ImagesCat. No.: HY-145046CAS No.: 2359689-76-0SOS1-IN-3 is a potent SOS1 (son of sevenless homolog 1) inhibitor with an IC50 of 5 nM. SOS1-IN-3 has anticancer effects (WO2019122129A1; compound I-1).
-
SOS1-IN-27
0 ImagesCat. No.: HY-184423SOS1-IN-27 is a potent, selective allosteric SOS1 inhibitor with a KD of 14 nM and SOS1-KRAS binding IC50 of 1.6 nM. SOS1-IN-27 disrupts SOS1-KRAS interaction, inhibits MAPK/PI3K signaling, induces G1 arrest and tumor cell apoptosis. SOS1-IN-27 serves as a valuable tool compound for pan-KRAS-driven colorectal cancer studies.
-
SOS1-IN-12
0 ImagesSOS1-IN-12 is a potent son of sevenless homolog 1 (SOS1) inhibitor with a Ki of 0.11 nM for SOS1 and an IC50 of 47 nM for pERK. SOS1-IN-13 can be used for researching anticancer.
-
SOS1-IN-17
0 ImagesCat. No.: HY-168716SOS1-IN-17 (Compound 8d) is an orally active inhibitor for SOS1-KRASG12C interaction with an IC50 of 5.1 nM. SOS1-IN-17 inhibits ERK phosphorylation in DLD-1 cell with an IC50 of 18 nM. SOS1-IN-17 exhibits anti-proliferative activity in KRASG12C mutated Mia-Paca-2 cell with an IC50 of 0.11 μM. SOS1-IN-17 exhibits antitumor efficacy against pancreatic cancer in mouse model.
-
SOS1-IN-10
0 ImagesCat. No.: HY-144213CAS No.: 2758690-15-0SOS1-IN-10 is a potent SOS1 inhibitor with an IC50 of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8).
-
SOS1/KRAS-IN-2
0 ImagesCat. No.: HY-181807SOS1/KRAS-IN-2 (Compound 20) is a SOS1::KRASG12C protein-protein interaction inhibitor with a IC50 of 4.11 nM. SOS1/KRAS-IN-2 blocks the interaction between SOS1 and KRASG12C. SOS1/KRAS-IN-2 induces cell Apoptosis. SOS1/KRAS-IN-2 exhibits anticancer activity against colorectal cancer and tongue squamous cell carcinoma.
-
SOS1-IN-24
0 ImagesCat. No.: HY-178044SOS1-IN-24 (Compound 15) is a SOS1 inhibitor with an IC50 of 0.398 μM. SOS1-IN-24 effectively disrupts SOS1::KRAS12D interaction. SOS1-IN-24 can be used for cancers like pancreatic and colorectal cancer research.
-
HH0043
0 ImagesCat. No.: HY-161714CAS No.: 2922069-42-7
-
NSC-658497
0 ImagesCat. No.: HY-19539CAS No.: 909197-38-2NSC-658497 is an effective inhibitor of Ras-GEF, SOS1. NSC-658497 binds to SOS1, competitively suppresses SOS1-Ras interaction, and dose-dependently inhibits SOS1 GEF activity. NSC-658497 showed dose-dependent efficacy in inhibiting Ras, downstream signaling activities, and associated cell proliferation.
-
SOS1-IN-20
0 ImagesCat. No.: HY-175244SOS1-IN-20 (Compound 12f) is an orally active SOS1 inhibitor with an IC50 of 5.11 nM against KRASG12C::SOS1. By disrupting the interaction between KRAS and SOS1, SOS1-IN-20 inhibits KRAS activation and downstream signal transduction. SOS1-IN-20 has an IC50 of 253 nM for p-ERK in PC-9 cells and 16.71 μM for hERG channel . SOS1-IN-20 can inhibit the proliferation of tumor cells and has antitumor activity.
-
SOS1-IN-26
0 ImagesCat. No.: HY-184422SOS1-IN-26 is a potent, orally active selective allosteric SOS1 inhibitor with a KD of 33 nM and SOS1-KRAS binding IC50 of 4.0 nM. SOS1-IN-26 disrupts SOS1-KRAS interaction, inhibits MAPK/PI3K signaling, induces G1 phase arrest and tumor cell apoptosis. SOS1-IN-26 serves as a balanced lead therapeutic candidate for pan-KRAS-driven colorectal cancer studies.
-
SOS1-IN-22
0 ImagesCat. No.: HY-175560CAS No.: 3092445-74-1SOS1-IN-22 is a son of sevenless homolog 1 (SOS1) inhibitor. SOS1-IN-22 can inhibit KRAS-G12C/SOS1 complex formation with an IC50 value of 40.28 nM. SOS1-IN-22 can reduce phosphorylation ERK levels. SOS1-IN-22 can be used for the research of cancer, such as pancreatic carcinoma and appendiceal carcinoma.
-
UC-857993
0 ImagesCat. No.: HY-124514CAS No.: 487001-04-7
-
SOS1-IN-4
0 ImagesCat. No.: HY-145047CAS No.: 2738392-83-9SOS1-IN-4 is a potent SOS1 inhibitor with an IC50 of 56 nM for KRAS-C12C/SOS1 interaction (WO2021228028 A1, example 65).
-
UC-773587
0 ImagesCat. No.: HY-122685CAS No.: 116679-70-0UC-773587 is a selective SOS1 catalytic activity inhibitor. UC-773587 binds to the catalytic site of Sos1 over HRas and ITSN (a RhoGEF) and inhibits nucleotide exchange with an IC50 value of 4.5 μM. UC-773587 mappes to the Ras switch II interaction region of the Sos1 catalytic site. UC-773587 can be used for the study of prostate cancer.
-
PROTAC SOS1 ligand 1
0 ImagesCat. No.: HY-168638CAS No.: 3027977-34-7PROTAC SOS1 ligand 1, a BI-3406 (HY-125817) analog, is a ligand for target SOS1 protein for PROTACT SIAIS562055 (HY-168637).
